-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 12, March 11, NMPA official website updated the drug approval information, Chengdu Better Pharmaceutical's Valsartan and Amlodipine Tablets (Ⅰ) 4 types of generic listing application was approved, the product is Better The first new product approved for the market this year.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Figure 1: New product approval status of Chengdu Better Pharmaceutical
Source: NMPA official website
Figure 2: The overall sales of Novartis' valsartan and amlodipine
Source: Minet database
According to data, Novartis' valsartan and amlodipine was approved to enter the domestic market in 2009, and subsequently monopolized the Chinese market for ten years.
According to data from Mi Nei.
com, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
com, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
Novartis’s monopoly of the Chinese market was broken in 2020.
Beijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Beijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Currently, Novartis’s Valsartan and Amlodipine (II) has not been approved for listing in China for the time being.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
Source: NMPA official website, Minet database
Statistics are as of March 11, if there are any omissions, please correct me!
Medical Network News, March 12, March 11, NMPA official website updated the drug approval information, Chengdu Better Pharmaceutical's Valsartan and Amlodipine Tablets (Ⅰ) 4 types of generic listing application was approved, the product is Better The first new product approved for the market this year.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Figure 1: New product approval status of Chengdu Better Pharmaceutical
Source: NMPA official website
Figure 2: The overall sales of Novartis' valsartan and amlodipine
Source: Minet database
According to data, Novartis' valsartan and amlodipine was approved to enter the domestic market in 2009, and subsequently monopolized the Chinese market for ten years.
According to data from Mi Nei.
com, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
com, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
Novartis’s monopoly of the Chinese market was broken in 2020.
Beijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Beijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Currently, Novartis’s Valsartan and Amlodipine (II) has not been approved for listing in China for the time being.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
Source: NMPA official website, Minet database
Statistics are as of March 11, if there are any omissions, please correct me!
Medical Network News, March 12, March 11, NMPA official website updated the drug approval information, Chengdu Better Pharmaceutical's Valsartan and Amlodipine Tablets (Ⅰ) 4 types of generic listing application was approved, the product is Better The first new product approved for the market this year.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Valsartan and amlodipine is Novartis's original research product.
In 2019, the total sales in China's public medical institution terminals and China's urban physical pharmacies have exceeded 2 billion yuan.
With the continuous impact of domestic high-end generic drugs, the market share of the original research pharmaceutical companies is steadily retreating.
Figure 1: New product approval status of Chengdu Better Pharmaceutical
Source: NMPA official website
Figure 2: The overall sales of Novartis' valsartan and amlodipine
Source: Minet database
According to data, Novartis' valsartan and amlodipine was approved to enter the domestic market in 2009, and subsequently monopolized the Chinese market for ten years.
According to data from Mi Nei.
com, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
Hospital hospital hospital pharmacy pharmacy pharmacycom, sales of this product have surged after entering the National Medical Insurance Catalogue in 2017.
In that year , the terminal sales of urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have broken.
1 billion yuan, which rose to 1.
6 billion yuan in 2019.
The sales growth rate of the original research products in the physical pharmacy terminals of Chinese cities in 2017-2019 has exceeded 20%, and the market potential is amazing.
Novartis’s monopoly of the Chinese market was broken in 2020.
Beijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Medicine Medicine MedicineBeijing Baiao Pharmaceutical won valsartan and amlodipine tablets in February last year (I) the first domestic imitation + the first review, and the Novartis terminal in China’s public medical institutions in 2020H1 The market share of pharmaceutical companies has declined.
It is expected that the market share of original research pharmaceutical companies will continue to shrink in the future under the attack of domestic pharmaceutical companies such as Huayuan Pharmaceutical, Jiangsu Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical .
Currently, Novartis’s Valsartan and Amlodipine (II) has not been approved for listing in China for the time being.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
The 4 types of generic listing applications of Guangzhou Bostao Controlled Release Pharmaceutical are under review and approval.
In addition, Zhejiang Huahai Pharmaceutical and Kunyao The group has also applied for the listing of 4 types of imitations of Valsartan and Amlodipine tablets, and the relevant acceptance number is under review and approval.
Source: NMPA official website, Minet database
Statistics are as of March 11, if there are any omissions, please correct me!
